See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. It is a type of drug called a monoclonal antibody, which works by targeting and blocking a specific protein in the body, called interleukin-17A, that plays a key role in inflammation [1].

Regarding the long-term effects of Cosentyx on immunity, the available information suggests that, like other similar medications, Cosentyx can affect the way the immune system works [2]. This is because it blocks the action of a specific protein that is also involved in the body's natural immune response [2]. However, the clinical significance of this effect is not fully understood, and more research is needed to fully understand the long-term implications of this immune system modification [2].

According to DrugPatentWatch.com, Cosentyx was first approved by the FDA in 2015, and its patent is set to expire in 2026 [3]. This means that, in the coming years, generic versions of the drug may become available, potentially increasing access to this medication and reducing its cost [3].

In summary, while Cosentyx can affect the immune system, more research is needed to fully understand the long-term implications of this effect. Patients taking Cosentyx should discuss any concerns about its potential long-term effects with their healthcare provider.

Sources:

* [1] Mayo Clinic. Cosentyx (secukinumab). <https://www.mayoclinic.org/drugs-supplements/cosentyx-secukinumab-subcutaneous-route/description/drg-20167321>.
* [2] National Psoriasis Foundation. Secukinumab (Cosentyx). <https://www.psoriasis.org/treatments/biologics/secukinumab-cosentyx>.
* [3] DrugPatentWatch.com. Cosentyx (secukinumab) Drug Patent Information. <https://www.drugpatentwatch.com/patent/cosentyx-secukinumab>.